knowledge -WSS

knowledge

author：focus 2025-09-30 17:05:41 - browse：7312

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： 4th of July breaks record for highest global temperature ever measured

WSS

Pfizer's Covid pill remains 89% effective in final analysis, company says

NYU radiologists take on the challenge of expensive MRI machines

Readout LOUD podcast: A CRISPR milestone, biotech mixology

In key trial, Verve's treatment lowers cholesterol levels in patients

NYU radiologists take on the challenge of expensive MRI machines

Community addresses injustice for Long Island mothers

explore

knowledge

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Why medical students are struggling with mental health

Dobbs anniversary: the lost opportunity of abortion as health care

Grail is spending more than ever lobbying Congress

Alkermes shareholders re

Surge of respiratory disease in China has likely explanation

The high cost of giving birth even with insurance

World's first CRISPR

Virginia high school admissions case could be legal follow

These geoengineering technologies could help combat the climate crisis, scientists say

focus

Doctor appointment wait times are getting worse

PhRMA sues HHS over Medicare drug price negotiation

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

FDA's Woodcock to retire early next year

New case study details death in closely watched Alzhiemer's trial

Congress must reauthorize a committee to support older Americans

explore

focus

leisure time

hotspot